IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average daily volume of 905,000 shares, the short-interest ratio is currently 10.4 days. Currently, 14.3% of the shares of the stock are sold short.
Insider Buying and Selling
In related news, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the transaction, the chief executive officer now owns 677,887 shares in the company, valued at approximately $30,870,973.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $46.02, for a total value of $92,040.00. Following the completion of the sale, the insider now owns 24,531 shares in the company, valued at approximately $1,128,916.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yujiro S. Hata sold 23,557 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at approximately $30,870,973.98. The disclosure for this sale can be found here. Insiders sold a total of 27,557 shares of company stock worth $1,248,886 in the last 90 days. Insiders own 5.00% of the company’s stock.
Institutional Trading of IDEAYA Biosciences
A number of hedge funds and other institutional investors have recently bought and sold shares of IDYA. BlackRock Inc. lifted its position in shares of IDEAYA Biosciences by 22.7% during the 2nd quarter. BlackRock Inc. now owns 4,355,696 shares of the company’s stock worth $102,359,000 after buying an additional 806,603 shares during the last quarter. Federated Hermes Inc. grew its position in shares of IDEAYA Biosciences by 14.8% in the 4th quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock valued at $138,185,000 after buying an additional 500,046 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of IDEAYA Biosciences by 17.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,566,278 shares of the company’s stock valued at $126,889,000 after purchasing an additional 535,909 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of IDEAYA Biosciences by 17.0% in the 4th quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company’s stock valued at $123,668,000 after purchasing an additional 504,275 shares during the period. Finally, State Street Corp grew its stake in IDEAYA Biosciences by 1.1% during the 2nd quarter. State Street Corp now owns 2,138,503 shares of the company’s stock worth $50,255,000 after buying an additional 24,186 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on IDYA
IDEAYA Biosciences Stock Performance
Shares of IDYA traded down $0.59 during midday trading on Wednesday, hitting $40.58. The company had a trading volume of 116,336 shares, compared to its average volume of 852,368. IDEAYA Biosciences has a 1 year low of $14.33 and a 1 year high of $47.74. The firm has a market capitalization of $3.03 billion, a P/E ratio of -20.57 and a beta of 0.80. The company’s 50-day simple moving average is $44.25 and its 200-day simple moving average is $36.91.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.05). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $8.84 million. The company’s revenue was down 3.0% on a year-over-year basis. Equities analysts predict that IDEAYA Biosciences will post -2.26 earnings per share for the current fiscal year.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
See Also
- Five stocks we like better than IDEAYA Biosciences
- How to buy stock: A step-by-step guide for beginners
- Abbott Laboratories Outlook is Healthy: Buy the Dip
- What Are Trending Stocks? Trending Stocks Explained
- ASML Fires Warning Shot For Tech Investors
- NYSE Stocks Give Investors a Variety of Quality Options
- Prologis Stock Leading U.S. Logistics Boom
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.